SCHEMBL3086959

SCHEMBL3086959

CCc1cc(-c2nnc(-c3cc(C)nc(NC(C)C)n3)o2)cc(C)c1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 13/20 0.41
GAA P10253 1/20 0.39
TSHR P16473 2/20 0.36
S1PR3 Q99500 11/20 0.36
MYC P01106 1/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 2/20 0.34
USP2 O75604 1/20 0.34
HSD17B10 Q99714 1/20 0.34
VCP P55072 1/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3085073 0.88 GAA (0.36) S1PR1GAATSHRS1PR3KDM4E
SCHEMBL3080691 0.88 S1PR1 (0.44) S1PR1S1PR3
SCHEMBL27752453 0.82 S1PR1 (0.44) S1PR1TSHRS1PR3MYCALDH1A1
SCHEMBL3082970 0.79 S1PR1 (0.37) S1PR1S1PR3
SCHEMBL3277355 0.77 S1PR1 (0.59) S1PR1TSHRS1PR3MYCALDH1A1
SCHEMBL2545632 0.76 S1PR1 (0.47) S1PR1TSHRS1PR3MYCALDH1A1
SCHEMBL3221506 0.74 TSHR (0.45) S1PR1GAATSHRS1PR3MYC
SCHEMBL10005028 0.72 S1PR1 (0.43) S1PR1TSHRS1PR3MYCALDH1A1
SCHEMBL3218799 0.72 S1PR1 (0.46) S1PR1TSHRS1PR3
SCHEMBL3080638 0.72 S1PR1 (0.46) S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD S1PR1 989/4885GAA 1847/4885TSHR 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.